AstraZeneca: Brilinta approved by FDA

(CercleFinance.com) - AstraZeneca's Brilinta (ticagrelor) has been approved by the US FDA in reducing the risk of heart attacks and strokes in patients with coronary artery disease, the most common heart condition today.


The FDA's approval was based on positive results from the Phase III THEMIS trial.

The trial showed a statistically significant reduction in the primary endpoint of major cardiovascular adverse events at 36 months with aspirin plus Brilinta 60 mg compared to aspirin alone in patients with CAD and type 2 diabetes at high risk for a first heart attack or stroke.

"The addition of ticagrelor to aspirin offers a new therapeutic option to decrease the likelihood of both heart attack and stroke, a significant advance in our ability to treat these high-risk patients,” the group said.


Copyright (c) 2020 CercleFinance.com. All rights reserved.